Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors

In May 1982, the US Food and Drug Administration (FDA) approved the use of streptozotocin to treat pancreatic neuroendocrine tumors (panNETs). Thus, this year marks 40 years since that landmark date. This review of streptozotocin to treat panNETs is intended to commemorate this anniversary. A historical perspective of the chemical structure, pharmacokinetics, and mechanism of action of streptozotocin is followed by data from prospective and retrospective clinical studies. The last section of the review addresses the latest aspects and takes note of the prospects that lie ahead on the future horizon of the use of streptozotocin to treat panNETs, including ongoing clinical trials. (c) 2022 S. Karger AG, Basel

Automated summary

This review provides a historical perspective on the use of streptozotocin to treat pancreatic neuroendocrine tumors (panNETs). It discusses the chemical structure, pharmacokinetics, and mechanism of action of streptozotocin, and presents data from prospective and retrospective clinical studies. The review also highlights the latest developments and future prospects for the use of streptozotocin in panNET treatment.